GCA
KRYS icon

Greenwood Capital Associates’s Krystal Biotech KRYS Stock Holding History

Greenwood Capital Associates’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Buy
1,495
+661
+79% +$197K 0.05% 207
2026
Q1 		$215K Buy
+834
New +$222K 0.02% 284

Other funds holding KRYS

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PIP
Palisades Investment Partners Santa Monica, California $352M AUM 76.79% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Greenwood Capital Associates's KRYS Position: Q2 2026 in Review

Greenwood Capital Associates increased its Krystal Biotech (KRYS) stake by 79% in Q2 2026, buying an estimated $197K and bringing the position to 1,495 shares worth $556K. The position accounts for 0.05% of the portfolio, ranked #207.

Greenwood Capital Associates first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 150 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Greenwood Capital Associates held 1,495 shares of Krystal Biotech worth $556K as of Q2 2026.
  • Greenwood Capital Associates bought 661 Krystal Biotech shares in Q2 2026, an estimated $197K.
  • Krystal Biotech made up 0.05% of Greenwood Capital Associates's portfolio in Q2 2026, its #207 holding.
  • Greenwood Capital Associates first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 150 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.